Samodzielny Publiczny Szpital Kliniczny Nr 1 W Lublinie

At Samodzielny Publiczny Szpital Kliniczny Nr 1 W Lublinie, a large share of research focuses on blood cancers and related marrow disorders, including acute myeloid leukemia, chronic lymphocytic leukemia, lymphomas, multiple myeloma, and myelodysplastic syndromes. These studies are mainly designed to test new treatment approaches, compare them with current standards, and improve disease control and survival outcomes.

• New therapies for acute myeloid leukemia and treatment-resistant disease
• Studies in chronic lymphocytic leukemia and small lymphocytic lymphoma to improve response and progression control
• Research in multiple myeloma, lymphoma, and myeloproliferative neoplasms to evaluate effectiveness and long-term safety

These trials reflect a strong oncology program with a focus on better targeted treatment options and more durable disease management.

The site also conducts clinical trials in eye diseases, especially conditions affecting vision and retinal health. Research includes neovascular age-related macular degeneration and uveitic macular edema, with the goal of evaluating new treatments that may help preserve or improve sight.

• Therapies aimed at protecting vision in retinal disease
• Studies for uveitic macular edema to improve swelling and visual outcomes
• Testing new approaches for age-related macular degeneration

Research in this field is centered on treatment effectiveness and better visual function for patients with chronic eye conditions.

Clinical trial activity at the Lublin hospital includes a broad set of immune system and skin disease studies, such as atopic dermatitis, psoriasis, prurigo nodularis, epidermolysis bullosa simplex, and pyoderma gangrenosum. The purpose of these trials is to assess new therapies that may reduce symptoms, improve skin healing, and offer longer-lasting relief.

• New treatment options for atopic dermatitis and chronic itching disorders
• Research in psoriasis to measure skin improvement and symptom control
• Studies in rare skin and connective tissue diseases to support better symptom management

These investigations combine common inflammatory conditions with rare dermatologic diseases, broadening the site’s research profile.

This research center is active in hemic and lymphatic diseases beyond cancer, including paroxysmal nocturnal hemoglobinuria, primary immune thrombocytopenia, hemophilia, and systemic mastocytosis. The trials are focused on testing therapies that may reduce bleeding, improve blood counts, or help control abnormal immune and complement activity.

• Studies for paroxysmal nocturnal hemoglobinuria to evaluate new complement-targeting treatments
• Research in immune thrombocytopenia and hemophilia to lower bleeding risk
• Trials in systemic mastocytosis to examine symptom control and disease activity

These projects are especially important for patients with uncommon conditions that require highly specialized care.

Some trials at the site address cardiovascular disease and surgery-related complications, including atherosclerotic disease, vascular disease, myocardial injury after non-cardiac surgery, and hypotension in non-cardiac surgery. The aim is to improve prevention, perioperative safety, and outcomes for patients at risk of heart and circulation problems.

• Studies to reduce myocardial injury after surgery
• Research on vascular disease affecting carotid, peripheral, and abdominal arteries
• Trials evaluating ways to improve perioperative cardiovascular safety

These studies support better risk management around surgery and in patients with underlying cardiovascular conditions.

The hospital also participates in trials for several solid tumors, including gastric cancer, biliary tract cancer, endometrial cancer, ovarian cancer, and advanced metastatic solid tumors. Research in this area is aimed at improving treatment effectiveness, delaying recurrence, and extending survival with newer cancer therapies.

• Studies in gastric and gastroesophageal junction cancer to improve outcomes after treatment
• Research in biliary tract cancer and endometrial cancer to test novel combination therapies
• Trials in ovarian cancer and other advanced tumors to compare treatment benefit

These oncology studies show a broad commitment to both common and difficult-to-treat cancers.